
    
      PKB116611 is an open-label Phase I/II study of the investigational drug GSK2110183 given in
      combination with carboplatin and paclitaxel to subjects with recurrent ovarian cancer. Phase
      I is a dose escalation evaluation of daily oral doses of GSK2110183 administered in
      combination with every 3 week carboplatin and paclitaxel to any subject with recurrent
      ovarian cancer. Phase II is a single arm evaluation of the clinical efficacy of the
      combination identified in Phase I to subjects with platinum-resistant ovarian cancer.
    
  